Shilpa Medicare Limited

SHILPAMED

INE790G01031

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:55 21/06/2024 pm IST			5-day change	1st Jan Change
579.3 ^INR	+1.41%		+8.81%	+75.33%

24/05	Transcript : Shilpa Medicare Limited, Q4 2024 Earnings Call, May 24, 2024
23/05	Shilpa Medicare Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI

Shilpa Medicare Limited Receives U.S. Food and Drug Administration Approval for its ANDA Irinotecan HCL Injection USP, 40 mg/2mL and 100 mg/5mL (20mg/mL) Single Dose Vials

January 01, 2019 at 09:20 am IST

Shilpa Medicare Limited has received U.S. Food and Drug Administration (USFDA) approval for its ANDA Irinotecan HCL Injection USP, 40 mg/2mL and 100 mg/5mL (20mg/mL) Single Dose Vials. Irinotecan injection is used in the treatment of patients with metastatic carcinoma of the colon or rectum.

Latest news about Shilpa Medicare Limited

Transcript : Shilpa Medicare Limited, Q4 2024 Earnings Call, May 24, 2024	24/05
Shilpa Medicare Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	23/05	CI
Shilpa Medicare Limited Announces Successful Completion of Early Clinical Development and Ongoing Phase 3 Clinical Trial of Its Newly Developed Drug "SML-007", for the Treatment of Non-Alalcoholic Fatty Liver Disease	14/05	CI
Shilpa Medicare Partner Amneal Pharma Launches Ready-to-Use Pemetrexed in US	18/04	MT
Shilpa Medicare Gets GMP Certification from Austrian Agency for Telangana, India Unit	17/04	MT
Shilpa Medicare Gets Board Nod to Launch QIP	09/04	MT
Shilpa Medicare's Life Science Arm Names CEO	28/03	MT
Shilpa Medicare's New Unit in Hyderabad, India Gets Zero Observations from US FDA	01/03	MT
Shilpa Medicare Gets Approval to Market Smoking Cessation Drug in Europe	26/02	MT
Transcript : Shilpa Medicare Limited, Q3 2024 Earnings Call, Feb 12, 2024	12/02
Shilpa Medicare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	08/02	CI
Shilpa Medicare Gets Germany's Marketing Approval for Rare Muscles Diseases Drug	19/01	MT
Shilpa Medicare Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	10/11	CI
Shilpa Medicare Acquires US-Based Pilnova Pharma	03/11	MT
Shilpa Medicare Limited Launches Naturally Derived Option for the Treatment of Oral Mucositis in India Under the Brand Name Oraal	11/23/11	CI
Shilpa Medicare Unit's API Manufacturing Plant Gets Clearance from Japanese Drug Regulator's Inspection	04/23/04	MT
Shilpa Medicare Gets UK Drug Regulator's Nod to Market Drug for Meniere's Syndrome Symptoms	04/23/04	MT
Shilpa Medicare Limited Receives Marketing Authorization from MHRA, UK, for Betahistine Dihydrochloride Orodispersible Films, 24 mg	01/23/01	CI
Shilpa Medicare's Manufacturing Facility in Telangana Gets Clearance from Brazilian Regulator	25/23/25	MT
Transcript : Shilpa Medicare Limited, Q1 2024 Earnings Call, Aug 11, 2023	11/23/11
Shilpa Medicare Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	10/23/10	CI
Shilpa Medicare Limited Announces Issuance of Redeemable Non-Convertible Debentures for its 2 Wholly Owned Subsidiaries	08/23/08	CI
Shilpa Medicare Gets Regulatory Nod for Pemetrexed Injections	01/23/01	MT
Shilpa Medicare Limited Receives Approval from CDSCO, New Delhi for Manufacturing and Sale of Lenvatinib Capsules, 12, 18 and 24 mg in India	29/23/29	CI
Shilpa Medicare to Raise Up to INR3.25 Billion from Rights Issue	23/23/23	MT

Chart Shilpa Medicare Limited

Duration

Period

More charts

Company Profile

Shilpa Medicare Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing of active pharmaceutical ingredients (APIs), formulation and development service. It is engaged in APIs, intermediates, formulations, new drug delivery systems, peptides / biotech products and specialty chemicals, and others. The Company supplies more than 30 oncology APIs including key products such as Capecitabine, Gemcitabine Hydrochloride, Pemetrexed, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various international markets including United States of America, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-Oncology API products include Ambroxol (Mucolytic agent), Tranexmic Acid and Ursodeoxycholic Acid. Its Injectable Dosage Forms include Myelodysplastic Syndrome, Breast Cancer, Multiple Myeloma, and more. Its Oral Solid Dosage Forms include Psoriasis, Prostate Cancer, Multiple Sclerosis, and others.

Sector

Pharmaceuticals

Calendar

12/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SHILPA MEDICARE LIMITED	+75.33%	602M
ELI LILLY AND COMPANY	+51.63%	796B
NOVO NORDISK A/S	+41.51%	628B
JOHNSON & JOHNSON	-5.10%	358B
MERCK & CO., INC.	+19.90%	331B
ABBVIE INC.	+9.95%	301B
ASTRAZENECA PLC	+17.66%	244B
ROCHE HOLDING AG	+3.39%	228B
NOVARTIS AG	+10.75%	214B
AMGEN INC.	+6.99%	165B

Other Pharmaceuticals